TA
MYGN icon

Tiedemann Advisors’s Myriad Genetics MYGN Stock Holding History

Tiedemann Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,175
Closed -$211K – 422
2017
Q2 		$211K Buy
+8,175
New +$174K 0.02% 420

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Tiedemann Advisors's MYGN Position: Q3 2017 in Review

Tiedemann Advisors sold out of Myriad Genetics (MYGN) in Q3 2017, closing a stake of 8,175 shares — an estimated $211K sold.

Tiedemann Advisors first reported a position in MYGN in Q2 2017 and held it in 1 quarter. The position peaked at $211K in Q2 2017. 220 funds tracked by Wall St. Rank hold MYGN as of Q3 2017.

  • Tiedemann Advisors reported no remaining Myriad Genetics position as of Q3 2017 after selling out during the quarter.
  • Tiedemann Advisors sold 8,175 Myriad Genetics shares in Q3 2017, an estimated $211K.
  • Tiedemann Advisors first reported a position in Myriad Genetics in Q2 2017 and held it in 1 quarter.
  • Tiedemann Advisors's Myriad Genetics position peaked at $211K in Q2 2017.
  • 220 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2017.

Based on Tiedemann Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.